These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 20562330)

  • 21. The importance of exogenous antigen in priming the human CD8+ T cell response: lessons from the EBV nuclear antigen EBNA1.
    Blake N; Haigh T; Shaka'a G; Croom-Carter D; Rickinson A
    J Immunol; 2000 Dec; 165(12):7078-87. PubMed ID: 11120837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.
    Ressing ME; Horst D; Griffin BD; Tellam J; Zuo J; Khanna R; Rowe M; Wiertz EJ
    Semin Cancer Biol; 2008 Dec; 18(6):397-408. PubMed ID: 18977445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epstein-Barr virus nuclear antigen 1-specific CD4+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells.
    Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
    Cancer Sci; 2008 Aug; 99(8):1633-42. PubMed ID: 18754877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitation, selection, and functional characterization of Epstein-Barr virus-specific and alloreactive T cells detected by intracellular interferon-gamma production and growth of cytotoxic precursors.
    Koehne G; Smith KM; Ferguson TL; Williams RY; Heller G; Pamer EG; Dupont B; O'Reilly RJ
    Blood; 2002 Mar; 99(5):1730-40. PubMed ID: 11861290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-uniform
    Burns DM; Ryan GB; Harvey CM; Nagy E; Hughes S; Murray PG; Russell NH; Fox CP; Long HM
    Front Immunol; 2019; 10():2489. PubMed ID: 31736946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.
    Khanna R; Bell S; Sherritt M; Galbraith A; Burrows SR; Rafter L; Clarke B; Slaughter R; Falk MC; Douglass J; Williams T; Elliott SL; Moss DJ
    Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10391-6. PubMed ID: 10468618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8(+) T-cell restoration.
    Porcu P; Eisenbeis CF; Pelletier RP; Davies EA; Baiocchi RA; Roychowdhury S; Vourganti S; Nuovo GJ; Marsh WL; Ferketich AK; Henry ML; Ferguson RM; Caligiuri MA
    Blood; 2002 Oct; 100(7):2341-8. PubMed ID: 12239141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CAR-T cells and TRUCKs that recognize an EBNA-3C-derived epitope presented on HLA-B*35 control Epstein-Barr virus-associated lymphoproliferation.
    Dragon AC; Zimmermann K; Nerreter T; Sandfort D; Lahrberg J; Klöß S; Kloth C; Mangare C; Bonifacius A; Tischer-Zimmermann S; Blasczyk R; Maecker-Kolhoff B; Uchanska-Ziegler B; Abken H; Schambach A; Hudecek M; Eiz-Vesper B
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33127653
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells.
    Moosmann A; Bigalke I; Tischer J; Schirrmann L; Kasten J; Tippmer S; Leeping M; Prevalsek D; Jaeger G; Ledderose G; Mautner J; Hammerschmidt W; Schendel DJ; Kolb HJ
    Blood; 2010 Apr; 115(14):2960-70. PubMed ID: 20103780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
    Burns DM; Crawford DH
    Blood Rev; 2004 Sep; 18(3):193-209. PubMed ID: 15183903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A quantitative assay for Epstein-Barr Virus-specific immunity shows interferon-gamma producing CD8+ T cells increase during immunosuppression reduction to treat posttransplant lymphoproliferative disease.
    Guppy AE; Rawlings E; Madrigal JA; Amlot PL; Barber LD
    Transplantation; 2007 Dec; 84(11):1534-9. PubMed ID: 18091531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infusions of Epstein-Barr virus-specific cytotoxic T lymphocytes as post-remission therapy in high-risk post-transplant lymphoproliferative disorder patients: report of two cases.
    Kim N; Sohn HJ; Oh JH; Jeon YW; Lee HJ; Cho HI; Chung BH; Yang CW; Kim TG; Cho SG
    Int J Hematol; 2018 May; 107(5):596-603. PubMed ID: 29188583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety.
    Hammer MH; Brestrich G; Mittenzweig A; Roemhild A; Zwinger S; Subklewe M; Beier C; Kurtz A; Babel N; Volk HD; Reinke P
    J Immunother; 2007; 30(8):817-24. PubMed ID: 18049333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors.
    Merlo A; Turrini R; Bobisse S; Zamarchi R; Alaggio R; Dolcetti R; Mautner J; Zanovello P; Amadori A; Rosato A
    J Immunol; 2010 May; 184(10):5895-902. PubMed ID: 20385879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD4 and CD8 T cell responses to tumour-associated Epstein-Barr virus antigens in nasopharyngeal carcinoma patients.
    Lin X; Gudgeon NH; Hui EP; Jia H; Qun X; Taylor GS; Barnardo MC; Lin CK; Rickinson AB; Chan AT
    Cancer Immunol Immunother; 2008 Jul; 57(7):963-75. PubMed ID: 18094968
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses.
    Gurer C; Strowig T; Brilot F; Pack M; Trumpfheller C; Arrey F; Park CG; Steinman RM; Münz C
    Blood; 2008 Aug; 112(4):1231-9. PubMed ID: 18519810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ex vivo priming of naïve T cells into EBV-specific Th1/Tc1 effector cells by mature autologous DC loaded with apoptotic/necrotic LCL.
    Popescu I; Macedo C; Zeevi A; Nellis J; Patterson KR; Logar A; Rowe D; Reyes J; Rao AS; Storkus WJ; Fung JJ; Metes D
    Am J Transplant; 2003 Nov; 3(11):1369-77. PubMed ID: 14525597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epstein-Barr virus (EBV)-associated post-transplantation lymphoproliferative disorder simultaneously affecting both B and T cells after allogeneic bone marrow transplantation.
    Chuhjo T; Yachie A; Kanegane H; Kimura H; Shiobara S; Nakao S
    Am J Hematol; 2003 Apr; 72(4):255-8. PubMed ID: 12666136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel method for detection of virus-specific CD41+ T cells indicates a decreased EBV-specific CD4+ T cell response in untreated HIV-infected subjects.
    Piriou ER; van Dort K; Nanlohy NM; van Oers MH; Miedema F; van Baarle D
    Eur J Immunol; 2005 Mar; 35(3):796-805. PubMed ID: 15724243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EBV-specific CD8+ T cell reactivation in transplant patients results in expansion of CD8+ type-1 regulatory T cells.
    Popescu I; Macedo C; Abu-Elmagd K; Shapiro R; Hua Y; Thomson AW; Morelli AE; Storkus WJ; Metes D
    Am J Transplant; 2007 May; 7(5):1215-23. PubMed ID: 17331111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.